USP Looks To Maximize Opportunity As China Builds Drug Standards
This article was originally published in PharmAsia News
A relationship initiated in the wake of a fatal heparin scandal between USP and the China Pharmacopeia Commission is going strong, presenting opportunities for companies like Sanofi and China’s Tasly as the Middle Kingdom gets set to expand drug standards.
You may also be interested in...
After Signing Pact With Chinese Regulators, U.S. Pharmacopeia Seeks To Develop New Tests To Help Prevent Deadly Episodes of Adulteration
BEIJING - After signing an agreement on cooperation with China's Center for Disease Control and Prevention in the wake of a series of contaminated drug and food scandals, leaders of the U.S. Pharmacopeial Convention are working to develop new tests that could be used to safeguard the global supply chain
U.S. Pharmacopeia Ramps Up Drug Quality, Safety Cooperation Across Asia With Four New Agreements With China, ASEAN States
BEIJING - In moves that could ultimately help elevate safety and quality standards for drugs produced across Asia, including those exported to North America, the United States Pharmacopeial Convention has signed a series of agreements with China and the Association of Southeast Asian Nations on closer scientific exchanges and joint testing of pharmaceuticals
China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.